The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Assessing the prevalence of CLDN18.2 in gastric/gastroesophageal cancers
The global prevalence of CLDN18.2, a biomarker associated with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, was investigated in two Phase III studies of zolbetuximab, namely SPOTLIGHT (NCT03504397) and GLOW (NCT03653507). These studies focused on patients with locally advanced unresectable or metastatic G/GEJ adenocarcinoma. In this interview, Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the findings of a biomarker analysis aimed to determine the frequency of CLDN18.2 expression in this patient population. Understanding the prevalence of CLDN18.2 can provide valuable insights into the potential use of zolbetuximab, a monoclonal antibody that targets CLDN18.2, as a therapeutic option in these patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
